VIOKASE 16 OPEN LABEL

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究和我们实验室对反馈抑制胰腺分泌的持续研究的最终期望是开发一种有效的胰酶制剂，能够持续地将其化合物释放到十二指肠。胰腺脂肪酶、淀粉酶和总蛋白水解酶的传输将使用肠道灌流和吸入方法进行评估，本实验室已在许多场合成功地使用了这种方法。15名慢性胰腺炎患者将被研究，他们都会有排泄量增加的粪便脂肪，胰腺功能不全。在饲喂状态下，比较添加和不添加胰酶时脂肪酶、淀粉酶和总蛋白酶的输送情况。研究的每一臂的CCK和CCK释放肽的水平将被检测。这项研究将评估Viokase 16将酶输送到十二指肠的效果。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The ultimate expectation of this study and of the continued studies of feedback inhibition of pancreatic secretion in our laboratory is to develop a potent pancreatic enzyme preparation which can release its compounds consistently into the duodenum. Delivery of pancreatic lipase, amylase and total protease will be evaluated utilizing an intestinal perfusion and aspiration methodology that this laboratory has utilized successfully on numerous occasions. Fifteen subjects with chronic pancreatitis will be studied, all of whom will have excretion of elevated amounts of fecal fat, pancreatic insufficiency. The delivery of lipase, amylase and total protease will be compared in a fed state with and without the addition of pancreatic enzymes. The levels of CCK and CCK releasing peptide will be assayed in each arm of the study. This study will evaluate the efficacy of Viokase 16 for the delivery of enzymes into the duodenum.